

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**SCHEDULE 13G**

Under the Securities Exchange Act of 1934

(Amendment No.   )\*

**AVEO Pharmaceuticals, Inc.**

(Name of Issuer)

**Common Stock**

(Title of Class of Securities)

053588307

(CUSIP Number)

**June 17, 2020**

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

---

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

---

1 Names of Reporting Persons.  
I.R.S. Identification Nos. of above persons (entities only)  
  
Cormorant Global Healthcare Master Fund, LP

---

2 Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

(b)

---

3 SEC Use Only

---

4 Citizenship or Place of Organization.  
  
Cayman Islands

---

5 Sole Voting Power  
  
0 shares

---

6 Shared Voting Power  
  
Number of Shares 1,278,045 shares

Beneficially Owned by Refer to Item 4 below.

---

Each Reporting Person With 7 Sole Dispositive Power  
  
0 shares

---

8 Shared Dispositive Power  
  
1,278,045 shares  
Refer to Item 4 below.

---

9 Aggregate Amount Beneficially Owned by Each Reporting Person  
  
1,278,045 shares  
Refer to Item 4 below.

---

10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  
 N/A

---

11 Percent of Class Represented by Amount in Row (9)\*  
  
4.95%  
Refer to Item 4 below.

---

12 Type of Reporting Person (See Instructions)  
  
PN (Partnership)

---

---

---

1 Names of Reporting Persons.  
I.R.S. Identification Nos. of above persons (entities only)  
  
Cormorant Global Healthcare GP, LLC

---

2 Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

(b)

---

3 SEC Use Only

---

4 Citizenship or Place of Organization.  
  
Delaware

---

5 Sole Voting Power  
  
0 shares

---

6 Shared Voting Power  
  
1,278,045 shares

---

Number of Shares Beneficially Owned by Each Reporting Person With

7 Sole Dispositive Power

---

8 Shared Dispositive Power  
  
1,278,045 shares

---

Refer to Item 4 below.

---

9 Aggregate Amount Beneficially Owned by Each Reporting Person  
  
1,278,045 shares  
Refer to Item 4 below.

---

10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  
  
 N/A

---

11 Percent of Class Represented by Amount in Row (9)\*  
  
4.95%  
Refer to Item 4 below.

---

12 Type of Reporting Person (See Instructions)  
  
OO (Limited Liability Company)

---

---

---

1 Names of Reporting Persons.  
I.R.S. Identification Nos. of above persons (entities only)  
  
Cormorant Asset Management, LP

---

2 Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

(b)

---

3 SEC Use Only

---

4 Citizenship or Place of Organization.  
  
Delaware

---

5 Sole Voting Power  
  
0 shares

---

Number  
of Shares  
Beneficially  
Owned by  
Each  
Reporting  
Person With

6 Shared Voting Power  
  
1,350,000 shares  
  
Refer to Item 4 below.

---

7 Sole Dispositive Power  
  
0 shares

---

8 Shared Dispositive Power  
  
1,350,000 shares  
  
Refer to Item 4 below.

---

9 Aggregate Amount Beneficially Owned by Each Reporting Person  
  
1,350,000 shares  
  
Refer to Item 4 below.

---

10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  
  
 N/A

---

11 Percent of Class Represented by Amount in Row (9)\*  
  
5.23%  
  
Refer to Item 4 below.

---

12 Type of Reporting Person (See Instructions)  
  
PN (Partnership)

---

---

1 Names of Reporting Persons.  
I.R.S. Identification Nos. of above persons (entities only)  
Bihua Chen

2 Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

(b)

3 SEC Use Only

4 Citizenship or Place of Organization.

United States

5 Sole Voting Power

0 shares

6 Shared Voting Power

1,350,000 shares

Beneficially Owned by

Refer to Item 4 below.

Each Reporting Person With

7 Sole Dispositive Power

0 shares

8 Shared Dispositive Power

1,350,000 shares

Refer to Item 4 below.

9 Aggregate Amount Beneficially Owned by Each Reporting Person

1,350,000 shares

Refer to Item 4 below.

10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

N/A

11 Percent of Class Represented by Amount in Row (9)\*

5.23%

Refer to Item 4 below.

12 Type of Reporting Person (See Instructions)

IN (Individual)

**Item 1.**

(a) Name of Issuer

AVEO Pharmaceuticals, Inc.

(b) Address of Issuer's Principal Executive Offices

30 Winter Street, Boston, MA 02108

**Item 2.**

(a) Name of Person Filing

Cormorant Global Healthcare Master Fund, LP  
Cormorant Global Healthcare GP, LLC  
Cormorant Asset Management, LP  
Bihua Chen

(b) Address of Principal Business Office or, if none, Residence

200 Clarendon Street, 52nd Floor  
Boston, MA 02116

(c) Citizenship

Cormorant Global Healthcare Master Fund, LP - Cayman Islands  
Cormorant Global Healthcare GP, LLC - Delaware  
Cormorant Asset Management, LP - Delaware  
Bihua Chen - United States

(d) Title of Class of Securities

Common Stock

(e) CUSIP Number

053588307

---

**Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c)

Insurance Company as defined in Section 3(a)(19) of the Act

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e)

An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

(k)

Group, in accordance with §240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership\*\*\***

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount Beneficially Owned\*\*\*

Cormorant Global Healthcare Master Fund, LP – 1,278,045 shares  
Cormorant Global Healthcare GP, LLC – 1,278,045 shares  
Cormorant Asset Management, LP – 1,350,000 shares  
Bihua Chen – 1,350,000 shares

(b) Percent of Class

Cormorant Global Healthcare Master Fund, LP – 4.95%  
Cormorant Global Healthcare GP, LLC – 4.95%  
Cormorant Asset Management, LP – 5.23%  
Bihua Chen – 5.23%

(c) Number of shares as to which such person has:

(i) sole power to vote or to direct the vote

Cormorant Global Healthcare Master Fund, LP - 0 shares  
Cormorant Global Healthcare GP, LLC - 0 shares  
Cormorant Asset Management, LP - 0 shares  
Bihua Chen - 0 shares

(ii) shared power to vote or to direct the vote

Cormorant Global Healthcare Master Fund, LP – 1,278,045 shares  
Cormorant Global Healthcare GP, LLC – 1,278,045 shares  
Cormorant Asset Management, LP – 1,350,000 shares  
Bihua Chen – 1,350,000 shares

(iii) sole power to dispose or to direct the disposition of

Cormorant Global Healthcare Master Fund, LP - 0 shares  
Cormorant Global Healthcare GP, LLC - 0 shares  
Cormorant Asset Management, LP - 0 shares

Bihua Chen - 0 shares

(iv) shared power to dispose or to direct the disposition of

Cormorant Global Healthcare Master Fund, LP – 1,278,045 shares

Cormorant Global Healthcare GP, LLC – 1,278,045 shares

Cormorant Asset Management, LP – 1,350,000 shares

Bihua Chen – 1,350,000 shares

\*\*\* Shares reported herein for Cormorant Asset Management, LP represent shares which are beneficially by Cormorant Global Healthcare Master Fund, LP (the “Master Fund”), as reported herein, and a managed account (the “Account”). Cormorant Global Healthcare GP, LLC serves as the general partner of the Master Fund. Cormorant Asset Management, LP serves as the investment manager to the Master Fund and the Account. Bihua Chen serves as the managing member of Cormorant Global Healthcare GP, LLC and the general partner of Cormorant Asset Management, LP. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or his pecuniary interest therein.

The percentages reported herein with respect to the Reporting Persons’ holdings are calculated based upon (i) a statement in the Issuer’s Prospectus Supplement dated June 16, 2020, as filed with the Securities and Exchange Commission on June 17, 2020, that there would be 24,580,616 shares of Common Stock of the Issuer outstanding immediately after public offering to which the Prospectus related, without taking into account any additional shares of Common Stock that might be issued to the underwriters of the offering upon the exercise of their overallotment option, and (ii) the statement in the Issuer’s press release dated June 19, 2020 that, at the closing of such offering, the Issuer sold an additional 1,225,000 shares of Common Stock in connection with the partial exercise by the underwriters of their option to purchase additional shares.

**Item 5. Ownership of Five Percent or Less of a Class**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [  ].

**Item 6. Ownership of More than Five Percent on Behalf of Another Person**

Not applicable.

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company**

Not applicable.

**Item 8. Identification and Classification of Members of the Group**

Not applicable.

**Item 9. Notice of Dissolution of Group**

Not applicable.

**Item 10. Certification**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

**Exhibits Exhibit**

**99.1** Joint Filing Agreement by and among the Reporting Persons.

---



**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.

June 29, 2020

CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP  
By: Cormorant Global Healthcare GP, LLC  
its General Partner

By: /s/ Bihua Chen  
Bihua Chen, Managing Member

CORMORANT GLOBAL HEALTHCARE GP, LLC  
By: /s/ Bihua Chen  
Bihua Chen, Managing Member

CORMORANT ASSET MANAGEMENT, LP  
By: Cormorant Asset Management GP, LLC  
its General Partner

By: /s/ Bihua Chen  
Bihua Chen, Managing Member

/s/ Bihua Chen  
Bihua Chen

**JOINT FILING AGREEMENT**

This Joint Filing Agreement, dated as of June 29, 2020, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Asset Management, LP and Bihua Chen (collectively, the “Filers”).

Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13D and/or 13G with respect to shares of Common Stock of AVEO Pharmaceuticals, Inc. beneficially owned by them from time to time.

Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13D and/or 13G (and any amendments thereto) on behalf of each of the Filers, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule.

This Joint Filing Agreement may be terminated by any of the Filers upon written notice or such lesser period of notice as the Filers may mutually agree.

Executed and delivered as of the date first above written.

CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP  
By: Cormorant Global Healthcare GP, LLC  
its General Partner

By: /s/ Bihua Chen  
Bihua Chen, Managing Member

CORMORANT GLOBAL HEALTHCARE GP, LLC  
By: /s/ Bihua Chen  
Bihua Chen, Managing Member

CORMORANT ASSET MANAGEMENT, LP  
By: Cormorant Asset Management GP, LLC  
its General Partner

By: /s/ Bihua Chen  
Bihua Chen, Managing Member

/s/ Bihua Chen  
Bihua Chen